Treatment strategies for refractory diabetic macular edema: Switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy

Expert Opinion on Biological Therapy

Volumn 16, Issue 3, 2016, Pages 365-374

  Hussain, Rehan M ^a   Ciulla, Thomas A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MIDWEST EYE INSTITUTE   (United States)

Author keywords

Aflibercept; Avastin; Bevacizumab; Dexamethasone; Diabetic macular edema; DME; Eylea; Fluocinolone acetonide; Iluvien; Lucentis; Ozurdex; Ranibizumab; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CORTICOSTEROID; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; GLUCOCORTICOID; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY PERIOD; REVIEW; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DIABETIC RETINOPATHY; MACULAR EDEMA;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84957965316     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1131265     Document Type: Review

References (45)

1. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653-2664.
2. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102 (1):7-16.
3. Ferris FL III, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984;28 (Suppl):452-461.
4. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1 Early treatment diabetic retinopathy study research group. Arch Ophthalmol. 1985;103(12):1796-1806.
5. Morello CM, Etiology and natural history of diabetic retinopathy: an overview. Am J Health Syst Pharm. 2007;64:S3-7.
6. Boyer DS, Hopkins JJ, Sorof J, et al. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4(6):151-169.
7. Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-77 e35.
8. Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol. 2013;131(2):139-145.
9. Elman MJ, Qin H, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119(11):2312-2318.
10. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122(2):375-381.
11. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117 (11):2146-2151.
12. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078-86.
13. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972-979.
14. Ciulla TA, Harris A, Latkany P, et al. Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand. 2002;80(5):468-477.
15. Ehrlich R, Harris A, Ciulla TA, et al. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 2010;88(3):279-291.
16. Miller JW, Le Couter J, Strauss EC, et al. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120(1):106-114.
17. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
18. Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001;276 (10):7614-7620.
19. Zhang X, Zeng H, Bao S, et al. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27.
20. Noma H, Mimura T, Yasuda K, et al. Role of inflammation in diabetic macular edema. Ophthalmologica. 2014;232:127-135.
21. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17):11393-11398.
22. Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diabetes. 2013;4(2):19-26.
23. Arevalo JF, Sanches JG, Wu L, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American collaborative retina study group at 24 months. Ophthalmology. 2009;116(8):488-97, 1497 e1.
24. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26 (8):859-870.
25. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-2022.
26. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
27. Bressler NM, Varma R, Suner IJ, et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology. 2014;121(12):2461-2472.
28. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
29. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044-2052.
30. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247-2254.
31. Stewart MW. The clinical utility of aflibercept for diabetic macular edema. Diabetes Metab Syndr Obes. 2015;8:473-482.
32. Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203.
33. Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular agerelated macular degeneration. Cochrane Database Syst Rev. 2014;9:p. CD011230.
34. Dhoot DS, Pieramici DJ, Nasir M, et al. Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye. 2015;29(4):534-541.
35. Ciulla TA, Hussain RM, Ciulla LM, et al. Ranibizumab for diabetic macular edema refractory to multiple prior treatments. Retina. 2015 Nov 18 [Epub ahead of print].
36. Lim LS, Ng WY, Mathur R, et al. Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab. Clin Ophthalmol. 2015;9:1715-1718.
37. Wood EH, Karth PA, Moshfeghi DM, et al. Short-term outcomes of aflibercept therapy for diabetic macular edema in patients with incomplete response to ranibizumab and/or bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2015;46(9):950-954.
38. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121(10):1892-1903.
39. Boyer DS, Yoon YH, Belfort R Jr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.
40. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125-2132.
41. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609-614.
42. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473-2481.
43. Maturi RK, Bleau L, Saunders J, et al. A 12-month, singlemasked, randomized controlled study of eyes with persistent diabetic macular Edema after multiple anti-vegf injections to assess the efficacy of the dexamethasonedelayed delivery system as an adjunct to Bevacizumab compared with continued Bevacizumab monotherapy. Retina. 2015;35(8):1604-1614.
44. Kowalczuk L, Touchard E, Omri S, et al. Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PloS One. 2011;6(3):e17462.
45. Huang H, He J, Johnson D, et al. Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1alpha-VEGF pathway inhibition. Diabetes. 2015;64(1):200-212